Drug metabolism and pharmacokinetics (DMPK) play a critical role in advancing drug candidates from discovery to the clinic.  In this comprehensive Guide from Waters, discover how modern DMPK strategies can help reduce development risk, accelerate decision-making and build confidence in regulatory submissions.   Read now >>> hubs.ly/Q04ySFWG0

Build pharmacokinetic and immunogenicity assays without custom critical reagents! Discover how on 27 Oct, 14:00 GMT (10:00 EDT) with BioAgilytix. Join the webinar >>> hubs.ly/Q04zwtc70

What are the five most common LBA method development failures for ADCs? How can you avoid them? What core assays are required for regulatory submission?  We've got all the answers in this #infographic with @GyrosProteinTec.  Download now for free >>> hubs.ly/Q04z-PNc0

AAPS has released the program for the 2026 PharmSci 360 event taking place from 25–28 October at the Ernest N. Morial Convention Center (New Orleans, LA, USA). Symposia, keynotes, speaker spotlights, poster sessions, hot topic presentations and rapid-fire talks taking place at PharmaSci 360 will examine the current trends in pharmaceutical sciences. With five main tracks, topics include immunogenicity assessment for emerging modalities, patient-centric and decentralized sampling, ultra-sensitive and multiplexed bioanalysis, strategies for new approach methodologies (NAMs) and organ-on-chip, and the ever-present battle against regulatory ‘gray areas’. Here are some of the presentations and plenaries our Editors are looking forward to! ➡️ AAPS PharmSci 360 2026: what can conference attendees look forward to? - Bioanalysis Zone (hubs.ly/Q04BH2gb0)

Humanoid robot development in general is picking up speed.  June 2026 brought us something straight out of a sci-fi film: humanoid robots mastering pipettes, beakers and Erlenmeyer flasks on live TV. Government-sponsored research centers are now training these mechanical scientists for real-world lab work. But what part does this have to play in the bioanalytical industry? Ming Li from Alexion, AstraZeneca Rare Disease, provides a few thoughts ➡️ hubs.ly/Q04z0ntP0

The final White Paper in the vaccine LBA trilogy has been published in Bioanalysis, completing a 5-year endeavor to create an overarching vaccine assay validation document that began in early 2021. The series is the outcome of a collaborative effort by a working group of experts from 16 global vaccine manufacturers, national regulatory authorities, and a nonprofit global-health foundation convened under the Workshop on Recent Issues in Bioanalysis (WRIB). Part 2 offers clear guidance on the iterative process of LBA development, essential for ensuring long-term assay performance and regulatory confidence. More information here 👉 Development of LBA to support vaccine immunogenicity studies - Bioanalysis Zone (hubs.ly/Q04Bz3vp0)

Activin E – a liver-derived member of the transforming growth factor-ß superfamily and a key regulator of adipose tissue metabolism – has attracted considerable attention in recent years. In this #CaseStudy from @Resolian_ you’ll gain insight into how Activin E measurements can help give biologically meaningful assessment of target engagement and biological activity.   Find out more here >>>  hubs.ly/Q04zp-pm0

Looking to learn more on the industry’s shift from rigid, one-size-fits-all immunogenicity workflows toward fit-for-purpose bioanalytical strategies that prioritize clinical relevance over procedural convention?   Don’t miss out on this White Paper from @IQVIA_global >>>    hubs.ly/Q04zf-vn0

💡 New to biomarker assay development? You're not alone.  In this must-read #interview, Elizabeth Hickford discusses how @Resolian_ guides Sponsors at all experience levels through the complexities of biomarker assay development – from defining your context of use to selecting the right validation strategy. Get expert tips on what information to provide your CRO partner and how to avoid common pitfalls >>> hubs.ly/Q04zg5LL0

Learn about the impact of the US Food and Drug Administration’s latest guidance on #biomarkers and what this means for validation strategy in this Perspective from @Resolian_. Read the full Perspective, as part of our Spotlight, here >>> hubs.ly/Q04zq1fM0

Manual or semi-automated plate-based ligand binding assay workflows are particularly vulnerable to the run failures and reproducibility issues that drive repeat analyses and regulatory scrutiny. This is where @GyrosProteinTec’s microfluidic #immunoassay platform excels, offering key advantages over traditional LBA workflows.  Learn more in our 2-minute video ‘Addressing LBA challenges in ADC analysis’ >>> hubs.ly/Q04z-PRH0

Following US FDA approvals of Onpattro (2018), Comirnaty (2021), Spikevax (2022) and mRESVIA (2024), understanding immune responses elicited by LNP-based products has become increasingly important.  Hear from Lifeng Tian, Xun Wang and Monique Putman in our latest interview with @QPSHoldingsLLC >>> hubs.ly/Q04xMFVd0

See how leading organizations are accelerating bioanalytical operations in this webinar exploring automation, digital technologies and advanced experimental design across the entire workflow. Register >>> hubs.ly/Q04Bdn0r0

Check out our 2-minute video on ‘Evaluating current and emerging ADC analysis methods’ as a part of our latest In the Zone!  Watch now >>>  hubs.ly/Q04xXZsT0

💵 WIN a USD $100 voucher! We're giving away TWO vouchers to survey participants. All you need to do? Answer 8 quick questions about biomarkers in bioanalysis (takes ~5 minutes).  You'll also get access to exclusive results in an infographic format >>> hubs.ly/Q04zg4Jm0

Learn platform selection criteria for pharmacokinetic and immunogenicity assay development, plus strategies for accelerating sample testing to reach IND faster. Register today >>> hubs.ly/Q04zvQ0l0

Discover how modern DMPK strategies can help reduce development risk, accelerate decision-making and build confidence in regulatory submissions in this comprehensive Guide from Waters.   Download for free today! >>> hubs.ly/Q04ySFWV0

The National Medical Products Administration (NMPA) has given INNOVITA the green light to bring Quanterix's SIMOA® technology and neurology biomarker assays to China – advancing access to ultra-sensitive #biomarker testing. Read the full news story here >>>bioanalysis-zone.com/innovit… @QuanterixSimoa

Don’t forget to check out our upcoming webinar with Labcorp, ‘Platform PCR method considerations for supporting cell and gene therapies along the journey.’ Register now >>> hubs.ly/Q04ylLQV0

Don’t forget to check out our upcoming webinar with Bio-Rad, ‘From antibody generation to reporter assays: tools for biotherapeutic development.’ Register now >>> hubs.ly/Q04yX2DT0